Precigen Inc. received swift and full FDA approval for Papzimeos (zopapogene imadenovec), a gene therapy for adults with recurrent respiratory papillomatosis (RRP), a rare disease marked by benign tumors in the respiratory tract caused by chronic HPV infections. This approval bypassed traditional confirmatory trial requirements, reflecting a tailored approach for rare diseases. The treatment is projected to reach significant sales milestones, with the company’s stock surging following the announcement.